Jeffrey Nau, Oyster Point Pharma CEO
Feeling the heat of the bear market, eye disease biotech to implement 'expense streamlining' plan and lay off 50
The company behind an FDA-approved inhalable form of smoking cessation aid Chantix for dry eye disease is falling in line with quite a few other …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
